Zoledronate to prevent bone loss in acute multiple sclerosis

A randomised controlled trial to evaluate whether zoledronate prevents bone loss in acute multiple sclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN87039596

Enrollment

Registered

2009-05-05

Start date

2009-04-20

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis Nervous System Diseases Multiple sclerosis

Interventions

A single dose of intravenous zoledronate 5 mg/placebo prior to commencement of intravenous corticosteroid for acute exacerbation of multiple sclerosis symptoms. Blood samples taken on days 1, 2, 3, 7,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 - 65 years (either sex) with a diagnosis of multiple sclerosis (MS) 2. Acute flare up requiring treatment with a corticosteroid 3. Able to attend for study investigations and assessments 4. Willing and able to provide informed consent

Exclusion criteria

Exclusion criteria: 1. Previous diagnosis of osteoporosis 2. Bone therapy within previous 12 months 3. Previous bisphosphonate therapy at any time 4. Associated disorder that may affect bone metabolism 5. Pregnancy 6. Breastfeeding

Design outcomes

Primary

Measure	Time frame
A significant difference in serum type I collagen C-telopeptides (CTX) according to treatment group at day 7 of the study	—

Secondary

Measure	Time frame
Increased bone mineral density (BMD), measured at days 7, 90,180 and 360	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026